within Pharmacolibrary.Drugs.ATC.C;

model C07BA05
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 0.0175,
    adminDuration  = 600,
    adminMass      = 80 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 600,            
    Vdp             = 0.0012,
    k12             = 800,
    k21             = 800
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C07BA05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Propranolol and thiazides is a fixed-dose combination drug used for the treatment of hypertension. Propranolol is a non-selective beta-adrenergic blocker, while thiazides (such as hydrochlorothiazide) are diuretics that promote sodium and water excretion. This combination was more common in the past for high blood pressure but is less frequently prescribed today due to the development of newer antihypertensive agents.</p><h4>Pharmacokinetics</h4><p>No direct pharmacokinetic parameters for the fixed combination 'propranolol and thiazides' (C07BA05) were found in the literature; estimates are based on known values for individual drugs in healthy adults.</p><h4>References</h4><ol><li><p>Hu, Z, et al., &amp; Zhou, S (2005). Herb-drug interactions: a literature review. <i>Drugs</i> 65(9) 1239–1282. DOI:<a href=\"https://doi.org/10.2165/00003495-200565090-00005\">10.2165/00003495-200565090-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15916450/\">https://pubmed.ncbi.nlm.nih.gov/15916450</a></p></li><li><p>Manitpisitkul, P, et al., &amp; Heald, D (2014). Pharmacokinetic interactions between topiramate and diltiazem, hydrochlorothiazide, or propranolol. <i>Clinical pharmacology in drug development</i> 3(5) 378–387. DOI:<a href=\"https://doi.org/10.1002/cpdd.107\">10.1002/cpdd.107</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27129011/\">https://pubmed.ncbi.nlm.nih.gov/27129011</a></p></li><li><p>Huang, W, et al., &amp; Wang, P (2020). Vanillin enhances the passive transport rate and absorption of drugs with moderate oral bioavailability in vitro and in vivo by affecting the membrane structure. <i>Food &amp; function</i> 11(1) 700–710. DOI:<a href=\"https://doi.org/10.1039/c9fo02846c\">10.1039/c9fo02846c</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31909774/\">https://pubmed.ncbi.nlm.nih.gov/31909774</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C07BA05;
